Logo image of BTTX

BETTER THERAPEUTICS INC (BTTX) Stock Fundamental Analysis

NASDAQ:BTTX - Nasdaq - US08773T1043 - Common Stock - Currency: USD

0.0446  +0.01 (+27.43%)

After market: 0.036 -0.01 (-19.28%)

Fundamental Rating

1

Taking everything into account, BTTX scores 1 out of 10 in our fundamental rating. BTTX was compared to 39 industry peers in the Health Care Technology industry. Both the profitability and financial health of BTTX have multiple concerns. BTTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BTTX had negative earnings in the past year.
BTTX had a negative operating cash flow in the past year.
BTTX Yearly Net Income VS EBIT VS OCF VS FCFBTTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

With a Return On Assets value of -294.55%, BTTX is not doing good in the industry: 97.50% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -294.55%
ROE N/A
ROIC N/A
ROA(3y)-84.16%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BTTX Yearly ROA, ROE, ROICBTTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 0 1K 2K 3K 4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BTTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BTTX Yearly Profit, Operating, Gross MarginsBTTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022

More info and screens

0

2. Health

2.1 Basic Checks

Compared to 1 year ago, BTTX has more shares outstanding
Compared to 1 year ago, BTTX has a worse debt to assets ratio.
BTTX Yearly Shares OutstandingBTTX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 5M 10M 15M 20M
BTTX Yearly Total Debt VS Total AssetsBTTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -27.22, we must say that BTTX is in the distress zone and has some risk of bankruptcy.
BTTX's Altman-Z score of -27.22 is on the low side compared to the rest of the industry. BTTX is outperformed by 90.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -27.22
ROIC/WACCN/A
WACCN/A
BTTX Yearly LT Debt VS Equity VS FCFBTTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 0 20M -20M

2.3 Liquidity

BTTX has a Current Ratio of 0.57. This is a bad value and indicates that BTTX is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.57, BTTX is doing worse than 85.00% of the companies in the same industry.
BTTX has a Quick Ratio of 0.57. This is a bad value and indicates that BTTX is not financially healthy enough and could expect problems in meeting its short term obligations.
BTTX has a worse Quick ratio (0.57) than 82.50% of its industry peers.
Industry RankSector Rank
Current Ratio 0.57
Quick Ratio 0.57
BTTX Yearly Current Assets VS Current LiabilitesBTTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 43.07% over the past year.
EPS 1Y (TTM)43.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BTTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.54% yearly.
BTTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 545.71% yearly.
EPS Next Y50.82%
EPS Next 2Y18.02%
EPS Next 3Y10.36%
EPS Next 5Y11.54%
Revenue Next Year-100%
Revenue Next 2Y2982.21%
Revenue Next 3Y922.61%
Revenue Next 5Y545.71%

3.3 Evolution

BTTX Yearly Revenue VS EstimatesBTTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B 2B
BTTX Yearly EPS VS EstimatesBTTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BTTX. In the last year negative earnings were reported.
Also next year BTTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BTTX Price Earnings VS Forward Price EarningsBTTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BTTX Per share dataBTTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.02%
EPS Next 3Y10.36%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BTTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BETTER THERAPEUTICS INC

NASDAQ:BTTX (3/15/2024, 8:00:03 PM)

After market: 0.036 -0.01 (-19.28%)

0.0446

+0.01 (+27.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)11-09 2023-11-09/bmo
Earnings (Next)03-27 2024-03-27/amc
Inst Owners0.01%
Inst Owner Change0%
Ins Owners17.48%
Ins Owner Change0%
Market Cap2.22M
Analysts82.5
Price Target5.36 (11917.94%)
Short Float %0%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.65%
Min EPS beat(2)24.59%
Max EPS beat(2)24.71%
EPS beat(4)4
Avg EPS beat(4)31.59%
Min EPS beat(4)24.59%
Max EPS beat(4)48.68%
EPS beat(8)6
Avg EPS beat(8)9.91%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.15
EYN/A
EPS(NY)-1.02
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS0
BVpS-0.2
TBVpS-0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -294.55%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-84.16%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.34%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.57
Quick Ratio 0.57
Altman-Z -27.22
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.75%
EPS Next Y50.82%
EPS Next 2Y18.02%
EPS Next 3Y10.36%
EPS Next 5Y11.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y2982.21%
Revenue Next 3Y922.61%
Revenue Next 5Y545.71%
EBIT growth 1Y50.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y5.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.13%
OCF growth 3YN/A
OCF growth 5YN/A